Latest News
Lithium Ionic (LTH.V) is up 50% in 3 months, and is moving toward production
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Medexus Pharma (MDP.T) – Investor Roundtable Video #3
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public markets pitfalls.
Today, we return to Medexus Pharmaceuticals (MDP.T), a Canadian-based specialty pharma company making waves. We discuss their recent financials, their bargain trading price compared to revenue and the near-term growth potential with the possible addition of treosulfan, a leading-edge stem cell replacement drug.
Enjoy!
Related Posts
Potential of Medexus Pharmaceuticals: Chris Parry gets into what investors are missing
Medexus Pharma (MDP.TO) Breaks Records: A Deep Dive into Quarterly Earnings, Portfolio Growth, and Future Opportunities
Medexus Pharmaceuticals (MDP): A Roller Coaster Ride to Success
Medexus Pharmaceuticals Sets New Revenue Records and Continues Expansion with Innovative Products and Financing
Medexus Pharmaceuticals (MDP.T) deals with its debentures
Medexus CEO (MDP.T) on creating Canada’s specialty pharma success story
More on MDP.T
Medexus (MDP.T) CEO explains sudden drop
Medexus Pharmaceuticals’ (MDP.T) financials are coming!
Medexus Pharma (MDP.T) is an arbitrage in the making
Medexus Pharmaceuticals (MDP.T) building serious value
Analysts say this specialty pharma stock is on track for a record $100 million USD 2023
Medexus Pharmaceuticals (MDP.T) – First Glance with Jody Vance E111